
    
      It is an open labelled, randomized, multi-center phase III clinical trail.A total of 1108
      patients with resected stage IB to stage IIIA non-small cell lung cancer will either ether
      the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus
      cisplatin randomly. The primary end point was overall survival; principal secondary end
      points were recurrence-free survival and the toxicity and safety of the regimens.The major
      inclusive criteria are pathological confirmed non-small cell lung cancer after complete
      resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked
      for further investigation. All of the enrolled patients will be followed up until death or
      over 5 years.
    
  